Evropska unija - malteščina - EMA (European Medicines Agency)

chiesi farmaceutici spa - kaffeina citrate - apnea - psychoanaleptics, - it-trattament tal-primarja apnea tal-trabi tat-twelid qabel iż-żmien.

Evropska unija - malteščina - EMA (European Medicines Agency)

zoetis belgium sa - virus modifikat ħaj tas-sindrome riproduttiv u respiratorju tal-ħnieżer - immunologicals for suidae, live viral vaccines - majjali - għall-immunizzazzjoni attiva tal-klinikament f'saħħithom-ħnieżer mill-1 ta'kuljum ta'l-età fil-respiratorja fil-majjali u l-riproduttiva sindromu (prrs) tal-virus kontaminati-ambjent, biex inaqqas viremja u fl-imnieħer jixħtu ikkawżata minn infezzjoni bil-varjanti ewropej tal-prrs virus (ġenotip 1). - simna tal-ħnieżer: barra minn hekk, it-tilqima tal-kienu seronegattivi għal 1-ġurnata qżieqeż intweriet li tnaqqas b'mod sinifikanti leżjonijet fil-pulmun kontra l-isfida amministrati fis-26 ġimgħa wara t-tilqima. it-tilqima ta 'qżieqeż seronegattivi ta' ġimgħatejn kienet murija li tnaqqas b'mod sinifikanti l-leżjonijiet tal-pulmun u tfaqqa 'mill-ħalq kontra l-isfida mogħtija f'28 ġurnata u f'16-il ġimgħa wara l-vaċċinazzjoni. il-qżieqeż u majjaliet: barra minn hekk, qabel it-tqala tilqim ta klinikament f'saħħithom-ħnieżer nisa żgħar u majjaliet, jew seropożittivi jew kienu seronegattivi għal, intweriet li tnaqqas l-infezzjoni transplaċentali kkawżata mill-prrs virus waqt it-tielet trimestru tat-tqala, u biex jitnaqqsu l-assoċjat impatt negattiv fuq il-prestazzjoni riproduttiva (tnaqqis ta 'l-okkorrenza ta' trabi li jitwieldu mejta, tal-qażquż viremija fit-twelid u fil-ftim, tal-pulmun u leżjonijiet tal-tagħbija virali fil-pulmuni fil-qżieqeż fil-ftim).

Evropska unija - malteščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomide - majloma multipla - immunosoppressanti - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) huwa indikat għall-kura ta ' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal trapjant tal -. lenalidomide qbil flimkien ma 'dexamethasone hu indikat għall-kura ta' majeloma multipla f'pazjenti adulti li jkunu rċevew mill-anqas terapija waħda qabel. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Evropska unija - malteščina - EMA (European Medicines Agency)

gedeon richter plc. - ulipristal acetate - leiomyoma - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - ulipristal acetate huwa indikat għall-kors wieħed ta 'kura ta' qabel l-operazzjoni tat-trattament minn moderat sa sever is-sintomi tal-fibrojdi fl-utru f'nisa adulti ta ' età riproduttiva. ulipristal acetate huwa indikat għat-trattament intermittenti moderat għal sever is-sintomi tal-fibrojdi fl-utru f'nisa adulti ta ' età riproduttiva li mhumiex eliġibbli għall-kirurġija.

Evropska unija - malteščina - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, kombinazzjonijiet - majjali (ħnienes) - għall-konkorrenti-prevenzjoni ta 'sinjali kliniċi tal-koċċidjożi (bħal dijarea) fit-trabi tat-twelid qżieqeż fuq l-irziezet kkonfermati b'-istorja tal-koċċidjożi kkawżati minn cystoisospora suis, u l-prevenzjoni ta 'defiċjenza ta' ħadid anemija.

Evropska unija - malteščina - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - majloma multipla - aġenti antineoplastiċi - bortezomib bħala monoterapija jew flimkien ma 'liposomal doxorubicin jew dexamethasone hu indikat għall-kura ta' pazjenti adulti b'progressiva majeloma multipla li rċevew mill-anqas terapija 1 minn qabel u li diġà għaddew jew li mhumiex tajbin għal trapjant b ' ċelluli staminali ematopojetiċi. bortezomib flimkien ma 'melphalan u prednisone huwa indikat għall-kura ta' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal doża għolja ta 'kimoterapija bi trapjant b' ċelluli staminali ematopojetiċi. bortezomib flimkien ma 'dexamethasone, jew ma' dexamethasone u thalidomide, huwa indikat għall-kura ta 'induzzjoni ta' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li huma eliġibbli għal doża għolja ta 'kimoterapija bi trapjant b' ċelluli staminali ematopojetiċi. bortezomib flimkien ma 'rituximab, cyclophosphamide, doxorubicin u prednisone huwa indikat għall-kura ta' pazjenti adulti li ma kienux ikkurati qabel f'forma ta'tubu taċ-ċelluli tal-limfoma li mhumiex tajbin għal trapjant b ' ċelluli staminali ematopojetiċi.

Evropska unija - malteščina - EMA (European Medicines Agency)

gennisium pharma - kaffeina citrate - apnea - psychoanaleptics, - it-trattament tal-primarja apnea tal-trabi tat-twelid qabel iż-żmien.

Evropska unija - malteščina - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosoppressanti - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) huwa indikat għall-kura ta ' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal trapjant tal -. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 u 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) huwa indikat għall-kura ta ' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal trapjant tal -. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 u 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Evropska unija - malteščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - iebes capsuleszerit huwa indikat flimkien ma ' prodotti mediċinali antiretrovirali oħra għat-trattament ta infettati bl-hiv pazjenti adulti u pazjenti pedjatriċi ('l fuq minn l-età ta'tliet xhur) biss meta l-mediċini antiretrovirali oħra ma jistgħux jintużaw. it-tul tat-terapija b'zerit għandha tiġi limitata għall-iqsar żmien possibbli. trab għall-ħalq solutionzerit huwa indikat flimkien ma ' prodotti mediċinali antiretrovirali oħra għat-trattament ta infettati bl-hiv pazjenti adulti u pazjenti pedjatriċi (mit-twelid) biss meta l-mediċini antiretrovirali oħra ma jistgħux jintużaw. it-tul tat-terapija b'zerit għandha tiġi limitata għall-iqsar żmien possibbli.

Evropska unija - malteščina - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infezzjonijiet ta 'virus sintetiku respiratorju - vaċċini - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. ara t-taqsimiet 4. 2 u 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.